Eureka AIR delivers breakthrough ideas for toughest innovation challenges, trusted by R&D personnel around the world.

Lovastatin silicon plastid of targeted breast cancer stem cell

A breast cancer stem cell, lovastatin technology, applied in the field of biomedicine, can solve problems such as low bioavailability, and achieve the effects of reducing toxic side effects, reducing damage, and improving stability

Active Publication Date: 2016-06-29
HUNAN NORMAL UNIVERSITY
View PDF2 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0007] The present invention aims to overcome the problem of low bioavailability of lovastatin in the prior art, and provides a lovastatin silicon body targeting breast cancer stem cells

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Lovastatin silicon plastid of targeted breast cancer stem cell
  • Lovastatin silicon plastid of targeted breast cancer stem cell
  • Lovastatin silicon plastid of targeted breast cancer stem cell

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] The lovastatin silicon body targeting breast cancer stem cells contains the following components by weight percentage:

[0045]

[0046] Preparation:

[0047] (1) Weighing the organic-inorganic composite lipid of the prescription amount according to the ratio of 2:1 to 5:1 (mass mg:volume mL) is added to the acidic ethanol solution and hydrolyzed at 40°C for 30min; wherein the acidic ethanol solution The pH is 3.0, and the preparation method is by adding dilute hydrochloric acid into an anhydrous ethanol solution, and adjusting the pH to 3.0 with a pH meter to obtain solution A;

[0048] (2) Dissolve phosphatidylethanolamine-polyethylene glycol 2000 and distearoylphosphatidylcholine in 7 mL of chloroform solution to obtain solution B; dissolve lovastatin powder in 54 μL of absolute ethanol , to obtain solution C; add solution B and solution C to solution A to obtain solution D, and put it into a 25mL eggplant-shaped bottle;

[0049] (3) Vacuum rotary evaporation in...

Embodiment 2

[0054] The lovastatin silicon body targeting breast cancer stem cells contains the following components by weight percentage:

[0055]

[0056] The preparation method is the same as in Example 1.

Embodiment 3

[0058] The lovastatin silicon body targeting breast cancer stem cells contains the following components by weight percentage:

[0059]

[0060] The preparation method is the same as in Example 1.

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

PropertyMeasurementUnit
particle diameteraaaaaaaaaa
particle diameteraaaaaaaaaa
Login to View More

Abstract

The invention discloses a lovastatin silicon plastid of a targeted breast cancer stem cell and a preparation method thereof.The lovastatin silicon plastid is prepared from, by weight, lovastatin 2%-30%, organic-inorganic compound lipid 20%-70%, phosphatidyl ethanolamine-polyethylene glycol 2000 1%-20% and distearoyl phosphatidylcholine 10%-60%.The lovastatin silicon plastid overcomes the shortcoming that the bioavailability of lovastatin drugs in the prior art is low.

Description

technical field [0001] The invention belongs to the technical field of biomedicine, and in particular relates to a lovastatin silicon body targeting breast cancer stem cells Background technique [0002] Breast cancer is one of the most common malignant tumors in women. North America and western developed countries are high-incidence areas of breast cancer, ranking first and second among female malignant tumors. In my country, the incidence of breast cancer has been increasing at an annual rate of 3-4% in recent years. Although the existing treatment methods have a good effect on early breast cancer, the effect on metastatic breast cancer, especially breast cancer with estrogen receptor (ER), progesterone receptor (PR), and HER2 triple negative, is not ideal. Exploring drugs against metastatic breast cancer, especially receptor-negative breast cancer is a very urgent task in the research of breast cancer therapy. [0003] In addition to the characteristics of self-renewal...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/127A61K31/366A61K47/24A61K47/34A61P35/00
CPCA61K9/1271A61K31/366A61K47/24
Inventor 邓锡云戴志飞宋柳江林丽姚慧贺光春
Owner HUNAN NORMAL UNIVERSITY
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Eureka Blog
Learn More
PatSnap group products